Last reviewed · How we verify
Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Part B: Multiple-dose ATM-AVI, Cohorts 1-4 | part-b-multiple-dose-atm-avi-cohorts-1-4 | Pfizer | Antiretroviral | HIV-1 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 1 drug in Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options:
- Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options treatment updates — RSS
- Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options treatment updates — Atom
- Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options treatment updates — JSON
Cite this brief
Drug Landscape (2026). Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/treatment-of-hiv-1-infection-in-adults-and-pediatric-patients-3-months-of-age-and-older-without-antiretroviral-treatment-options. Accessed 2026-06-10.
Related
- Treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older without antiretroviral treatment options full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing